 Study drug was administered subcutaneously a total of 26 times over a 24-month period. The first three doses were administered every 2 weeks induction phase; all subsequent dosing occurred monthly maintenance phase. Patients returned to the study center to receive study drug and have efficacy and safety assessments collected. The primary efficacy endpoint was the 2-hour peak C-peptide at Month 24. Other secondary analyses included AUC C-peptide, prescribed insulin usage, AUC blood glucose, HbA1c, hypoglycemic events, and hyperglycemic events. 